BridGene Biosciences Begins Dosing in Phase 1 Trial of TEAD Inhibitor for Solid Tumors

SAN JOSE, Calif., June 28, 2024 -- BridGene Biosciences, Inc., a pioneer in the field of covalent small molecule drugs targeting traditionally challenging targets, has announced the commencement of its Phase 1 clinical trial for BGC515, a novel TEAD inhibitor. This breakthrough drug was discovered using BridGene's revolutionary chemoproteomic platform known as IMTAC™. The initiation of this trial underscores the potential of BridGene's innovative chemoproteomic techniques.

The Phase 1 clinical study will involve participants in both the United States and China (NCT06452160). The primary aim is to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and early indications of antitumor efficacy of BGC515. The drug will be administered as a monotherapy to patients suffering from advanced solid tumors, including malignant mesothelioma, epithelioid hemangioendothelioma, and other solid tumors with abnormalities in the Hippo signaling pathway. The trial's principal investigator at the initial US site is Dr. Timothy Yap, Ph.D., FRCP, who is a Professor in the Department of Investigational Cancer Therapeutics and the Head of Clinical Development in the Therapeutics Discovery Division at the University of Texas MD Anderson Cancer Center.

"We are thrilled to initiate the clinical trial of BGC515 with our first patient. We anticipate this study will provide vital insights into the safety and efficacy of this promising compound," commented Jeremy Barton, M.D., Chief Medical Officer of BridGene Biosciences.

Ping Cao, Ph.D., Co-Founder and CEO of BridGene Biosciences, remarked, "The dosing of our first drug in clinical development from our chemoproteomic platform is a significant milestone for BridGene. This progress reflects our dedication to addressing unmet medical needs through innovative treatments. BGC515 signifies a significant advancement in targeting TEAD proteins, crucial elements in the Hippo pathway. We are proud of the rapid progress we have made in creating a robust pipeline that includes previously unreachable targets for major oncology and immunology diseases."

BridGene Biosciences is actively developing multiple new drug discovery programs and has more than a dozen potential opportunities in early-stage discovery.

About the Hippo Pathway and BGC515

The Hippo pathway is essential in cellular regulation, controlling the expression of certain genes through transcription factors YAP and TAZ. These factors operate in concert with TEAD proteins, the primary targets of BGC515. Activation of YAP and TAZ is a common trait in various human cancers, occurring through multiple mechanisms.

BGC515, developed in-house, is an orally-administered, covalent TEAD inhibitor.

About BridGene Biosciences

BridGene is a biotechnology company dedicated to discovering and developing innovative small molecules that target traditionally undruggable targets, offering new treatment avenues for diseases. Utilizing its proprietary chemoproteomic platform, IMTAC™, BridGene can screen small molecules against the entire proteome in live cells, identifying drug candidates for high-value, previously undruggable targets. The company leverages its proprietary, diverse covalent library of tagged, drug-like small molecules to achieve this goal. BridGene's mission is to enable breakthrough small-molecule drug discovery and expand treatment mechanisms for previously inaccessible targets. The company is advancing a diverse pipeline of first-in-class drugs targeting multiple disease areas.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!